Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

Advances in RA treatment require improved understanding of patient-specific therapy appropriateness, focusing on disease pathogenesis and heterogeneity. Current RA treatment algorithms lack biomarkers ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

RA is an autoimmune disease where the immune system mistakenly attacks the lining of joints, causing inflammation and potential joint damage. Treatment goals for RA include reducing inflammation and ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

The results of research by scientists at Trinity College Dublin and St. Vincent’s University Hospital offer new insights into the cellular and genetic features of joint inflammation in rheumatoid ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Weight loss drugs known as GLP-1 receptor agonists are sometimes referred to as “miracle drugs,” not only because they help people lose weight, but because they’ve also been shown to help with many ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.